QUINAZOLINE COMPOUNDS

THE INVENTION RELATES TO COMPOUNDS OF THE FORMULA I: WHEREIN RING C IS AS DEFINED HEREIN, FOR EXAMPLE INDOLYL, INDAZOLYL OR AZAINDOLYL; Z IS -O-, -NH-OR -S-; N IS 0-5; M IS 0-3; R1 AND R2 ARE DEFINED HEREIN INCLUDING GROUPS: (I) Q1X1 WHEREIN Q1 AND X1 ARE AS DEFMED HEREIN; (II) Q15W3 WHEREIN Q15 AND W3 ARE AS DEFINED HEREIN, (III) Q21W4C5-5ALKYLX1- WHEREIN Q21, W4 AND X1 ARE AS DEFINED HEREIN, (IV) Q28C1-5ALKYIX1- Q28C2-5ALKENY1X1-OR Q28C2-5ALKYNYLX1- WHEREIN Q28 AND X1 ARE AS DEFMED HEREIN AND (V) Q29C1-5ALKYLX1-, Q29C2-5ALKENYLX1- OR Q29C2-5ALKYNYLX1- WHEREIN Q29 AND X1 ARE AS DEFINED HEREIN; R2 CAN ALSO BE 6,7-METHYLENEDIOXY OR 6,7-ETHYLENEDIOXY; AND SALTS THEREOF; THEIR USE IN THE MANUFACTURE OF A MEDICAMENT FOR USE IN THE PRODUCTION OF AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT IN WARM-BLOODED ANIMALS; PROCESSES FOR THE PREPARATION OF SUCH COMPOUNDS; INTERMEDIATES USED IN SUCH PROCESSES; PROCESSES FOR MAKING SUCH INTERMEDIATES; PHARMACEUTICAL COMPOSITIONS CONTAINING A COMPOUND OF FORMULA I OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND METHODS OF TREATING DISEASE STATES INVOLVING ANGIOGENESIS BY ADMINISTERING A COMPOUND OF FORMULA I OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF. THE COMPOUNDS OF FORMULA I INHIBIT THE EFFECTS OF VEGF, A PROPERTY OF VALUE IN THE TREATMENT OF A NUMBER OF DISEASE STATES INCLUDING CANCER AND RHEUMATOID ARTHRITIS.